Bioxytran, Inc. · OTC:BIXT
Bioxytran — Investor Presentation (September 2018)
17 slides from Bioxytran's investor presentation, Sep 24, 2018
Slide 1: David Platt contact details
2018-09-24 David Platt [email protected] (617)-510-2539
Slide 2: Forward Looking Statement
2018-09-24 Forward Looking Statement This report contains forward-looking statements concerning, among other things, possible applications for marketing approval and other regulatory matters, clinical trials, plans for the development of BioXyTran and business strategies. These forward-looking state
Slide 3: Mission Statement
2018-09-24 Mission Statement BioXyTran, Inc. is a biopharmaceutical company to develop first-in-class treatments for hypoxic conditions and necrosis 3
Slide 4: Team
2018-09-24 Team Management Independent Board of Directors Advisory Board Avraham Mayevsky, PhD David Platt, Ph.D/CEO Alan Hoberman, PhD Worldwide authority in the field of Ph.D in Chemical Engineering, Hebrew U. Executive Director of Operations minimal invasive monitoring of tissue of Jerusalem; Wei
Slide 5: The Brain Stroke Epidemic
2018-09-24 The Brain Stroke Epidemic Region Strokes Population Survivors Direct cost Indirect cost (millions) (millions) (millions) (billions) (billions) US 0.8 321 5.8 $44 $22 EU (+GB) 1.1 743 3.4 $28 $16 CN 2.5 1,371 7.5 estimated $74 World 17.0 7,500 33.0 estimated $184 5
Slide 6: Time Is Brain, Quantified
2018-09-24 Time Is Brain, Quantified Copyright C 2017 Jeffrey L. Saver, MD Estimated Pace of Neural Circuitry Loss in a Typical Stroke Neurons lost Synapses lost Myelinated fibers lost Accelerated aging Per stroke 300 million 2 trillion 1,800 km/1,100 miles 9 years (average) Per hour 120 million 830
Slide 7: Blood Clot Caused by Coagulation
2018-09-24 Blood Clot Caused by Coagulation Image of red blood-cells caught in the mech of fibrins causing a blood clot. Copyright C 2010 Pearson Education, Inc 7
Slide 8: BXT-25 – An Oxygen Bridge
2018-09-24 BXT-25 – An Oxygen Bridge BXT-25 polymer 8
Slide 9: BXT-25 - Stabilized Oxygen-carrying Protein
2018-09-24 BXT-25 - Stabilized Oxygen-carrying Protein Red blood cells, RBCs Hemoglobin (Hb) Native Hb (oxygen-carrying protein) + Tetramer 64 kD Dimer 32 kD Stabilized Hb tetramer with co-polymer 50 kD BXT stabilized Hb polymer – 50 kD • Low viscosity • Non-immunogenic • Universally compatible with
Slide 10: Proprietary Manufacturing Process of BXT-25
2018-09-24 Proprietary Manufacturing Process of BXT-25 Collect BXT-25 is mixed with a controlled Extract Hemoglobin Extract Heme and Purify and crosslink saline solution, to be IV- source Red Protein reattach to a polymer infused by an ER team blood cells Key Assays for BXT-25 chemical and structura
Slide 11: Proof of Concept of BXT-25 in Animals
2018-09-24 Proof of Concept of BXT-25 in Animals • Absence of nitric oxide scavenging, no increased blood pressure in diabetic mice (Harvard Medical School, 2013) • No toxicity from replacing 90% of the blood in dogs with similar chemistry to BXT-25: https://www.hindawi.com/journals/ccrp/2014/864237
Slide 12: FDA Approved OXYSENSE Technology
2018-09-24 FDA Approved OXYSENSE Technology TM a clinical end-point for measuring oxygen delivery to the brain in real-time Flat probe Treated Aneurysm Our licensed technology allows for a rapid, cost-effective and validated development of safe new molecules that address unmet medical needs in disea
Slide 13: Current limited effect treatments
2018-09-24 Current limited effect treatments Our competition is tPA and similar drugs, aiming to dissolve, or remove, a clot. These are time-consuming and require an MRI since blood-thinners are fatal in hemorrhagic strokes. Drug/Treatment Company Description Genentech, Thrombolytic agent used to br
Slide 14: BXT-251 - Organ Preservation
2018-09-24 BXT-251 - Organ Preservation Eurotransplant Annual Report 2010 Up to 72% of donated organs go to waste BXT-251, indicated to prolong extracorporeal circulation and preservation of organs for transplant during transport or storage from hours to days Typical and maximum preservation limits
Slide 15: Future Development
2018-09-24 Future Development US market potential for BXT-25 is $10B, including: • Cerebrovascular Accidents • Anemia Treatment • Wound Healing • Traumatic Brain Injury (TBI) • Cancer • Acute Coronary Syndromes • Anti-Necrosis • Human Organ Transplants Product Description Objective Timeline BXT-251
Slide 16: Business Development & Strategy
2018-09-24 Business Development & Strategy Intellectual Property (IP) One issued US patent (US6245316B1) Additional applications to strengthen our IP position are ongoing Business Development Strategy Safety Studies In Healthy Volunteers Phase I Efficacy Study In Stroke Patients Phase II Establish l
Slide 17: BioXyTran, Inc. contact
2018-09-24 BioXyTran, Inc. 233 Needham St., Suite 300 Newton MA, 02464 (617)-454-1199 www.bioxytraninc.com David Platt [email protected] (617)-510-2539 17